Halozyme, Inc.

Halozyme's business is primarily focused on its proprietary and patented recombinant human hyaluronidase enzyme, rHuPH20. The company's development pipeline is concentrated in clinical stage and pre-clinical stage oncology products, including its proprietary investigational drug, PEGPH20, a pegylated version of rHuPH20, which targets hyaluronan (HA) high tumors. The company is in various phases of clinical trials with PEGPH20 across multiple solid tumor types, including pancreatic cancer, non-small cell lung cancer (NSCLC), and gastric cancer, to test the drug's safety and efficacy. Halozyme has one FDA approved product (Hylenex recombinant, hyaluronidase human injection). The company also licenses its drug delivery technology Enhanze to other biopharmaceutical companies, including Roche, Baxalta, Pfizer, Janssen, AbbVie,

Bristol Myers Squibb and Lilly.

Approved products

Hylenex: Approved by the U.S. Food and Drug Administration (FDA) on 12/02/2005. Hylenex is a hyaluronidase (human recombinant) injection indicated for use in subcutaneous fluid administration, dispersion and absorption of injected drugs, and subcutaneous urography.

Technology

Enhanze: Uses recombinant human hyaluronidase to degrade HA and aids in the absorption and dispersion of co-administered injected drugs. Halozyme licenses its Enhanze drug delivery platform technology to other biopharmaceutical companies to enable intravenous to subcutaneous administration conversion and dose optimization.

Product candidates

PEGPH20: A PEGylated drug candidate based on Halozyme's proprietary rHuPH20 enzyme (a recombinant human hyaluronidase enzyme). It breaks down or depletes hyaluronan (HA), which can build up in certain tumors. The goal of PEGPH20 is to break down HA so that some anti-cancer therapies and activated immune cells can better reach the cancer cells of HA-high tumors. On November 4, 2019, Halozyme announced it has halted development of PEGPH20.